113 related articles for article (PubMed ID: 2050175)
1. The pharmacokinetics and pharmacodynamics of lisuride in healthy volunteers after intravenous, intramuscular, and subcutaneous injection.
Krause W; Mager T; Kühne G; Duka T; Voet B
Eur J Clin Pharmacol; 1991; 40(4):399-403. PubMed ID: 2050175
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: effect on plasma prolactin level.
Hümpel M; Nieuweboer B; Hasan SH; Wendt H
Eur J Clin Pharmacol; 1981; 20(1):47-51. PubMed ID: 7308272
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of lisuride after subcutaneous infusion.
Krause W; Nieuweboer B; Ruggieri S; Stocchi F; Suchy I
J Neural Transm Suppl; 1988; 27():71-4. PubMed ID: 3165439
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of terguride following intramuscular administration in cows and goats.
Lapka R; Krejci P; Lidický J; Frühaufová M; Rezábek K
Acta Physiol Pol; 1989; 40(1):139-44. PubMed ID: 2603744
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride.
Krause W; Sauerbrey N; Gräf KJ
Eur J Clin Pharmacol; 1986; 31(2):165-8. PubMed ID: 3803415
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and endocrine effects of terguride in healthy subjects.
Krause W; Träger H; Kühne G; Sauerbrey N; Gräf KJ; Dorow R
Eur J Clin Pharmacol; 1990; 38(6):609-15. PubMed ID: 2373136
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers.
Trinchard-Lugan I; Ho-Nguyen Q; Bilham WM; Buraglio M; Ythier A; Munafo A
Eur Cytokine Netw; 2001; 12(3):391-8. PubMed ID: 11566619
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of the ergot derivative, transdihydrolisuride, in man.
Krause W; Dorow R; Nieuweboer B; Hasan SH
Eur J Clin Pharmacol; 1984; 27(3):335-9. PubMed ID: 6510462
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
Dychter SS; Harrigan R; Bahn JD; Printz MA; Sugarman BJ; DeNoia E; Haughey DB; Fellows D; Maneval DC
Clin Ther; 2014 Feb; 36(2):211-24. PubMed ID: 24486335
[TBL] [Abstract][Full Text] [Related]
10. [Lactation inhibition with various dosages of lisuride--prolactin secretion and effectiveness].
Strahl HJ; Göretzlehner G; Strahl S; Kunkel S
Zentralbl Gynakol; 1985; 107(5):300-3. PubMed ID: 4039514
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of recombinant human luteinizing hormone after intravenous, intramuscular, and subcutaneous administration in monkeys and comparison with intravenous administration of pituitary human luteinizing hormone.
Porchet HC; Le Cotonnec JY; Neuteboom B; Canali S; Zanolo G
J Clin Endocrinol Metab; 1995 Feb; 80(2):667-73. PubMed ID: 7852534
[TBL] [Abstract][Full Text] [Related]
12. Suppression of prolactin secretion by lisuride throughout the menstrual cycle and in hyperprolactinaemic menstrual disorders.
Bohnet HG; Hanker JP; Horowski R; Wickings EJ; Schneider HP
Acta Endocrinol (Copenh); 1979 Sep; 92(1):8-19. PubMed ID: 386688
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of cefotaxime in sheep.
Guerrini VH; Filippich L; English PB; Bourne DW
Am J Vet Res; 1983 Aug; 44(8):1488-91. PubMed ID: 6312852
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man.
Hümpel M; Krause W; Hoyer GA; Wendt H; Pommerenke G
Eur J Drug Metab Pharmacokinet; 1984; 9(4):347-57. PubMed ID: 6532807
[TBL] [Abstract][Full Text] [Related]
15. Aluminium toxicokinetics after intramuscular, subcutaneous, and intravenous injection of Al citrate solution in rats.
Weisser K; Göen T; Oduro JD; Wangorsch G; Hanschmann KO; Keller-Stanislawski B
Arch Toxicol; 2019 Jan; 93(1):37-47. PubMed ID: 30302509
[TBL] [Abstract][Full Text] [Related]
16. Circadian plasma level profile of lisuride in rats and mice after continuous administration via the diet.
Krause W; Reissmann F; Kühne G; Schöbel C
Arzneimittelforschung; 1995 Jan; 45(1):6-10. PubMed ID: 7893271
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep.
Cárceles CM; Escudero E; Fernández-Varón E; Marín P
Vet J; 2009 Jun; 180(3):343-7. PubMed ID: 18406644
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat. Single and multiple dosing studies.
Tanaka H; Kaneko T
Drug Metab Dispos; 1991; 19(1):200-4. PubMed ID: 1708329
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of interferon alpha-2b in healthy volunteers.
Radwanski E; Perentesis G; Jacobs S; Oden E; Affrime M; Symchowicz S; Zampaglione N
J Clin Pharmacol; 1987; 27(5):432-5. PubMed ID: 3693589
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic studies of highly purified human prolactin in normal human subjects.
Molitch ME; Raiti S; Baumann G; Belknap S; Reichlin S
J Clin Endocrinol Metab; 1987 Aug; 65(2):299-304. PubMed ID: 3597709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
